Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company’s 25-year innovation bet, and why it’s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark’s IGI platform after fifteen years of R&D. Saldanha talks through the platform’s pipeline, why Glenmark stays out of ADCs and CAR-T, how it’s building “Glenmark 3.0” across oncology, dermatology and respiratory, and why he still rates the US well ahead of China on innovation. The conversation also covers India’s licensing deals with Chinese biotechs, AI in drug discovery, and the GLP-1 market.

Listen in

You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin

Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

See omnystudio.com/listener for privacy information.

Glenmark Chief on Cracking the Multi-Specific Code

The Morning Brief

Glenmark Chief on Cracking the Multi-Specific Code